Aug 2026· Gaceta Sanitaria· Vol 40, pp.
102650
· 0 citations· 27 references
Medicine
TL;DR
Combining real-world data and DES can enable cost-utility studies to be conducted, thus streamlining the process of economic evaluation, and additional tools are required, such as probabilistic sensitivity analysis.
Abstract
INTRODUCTION
This study provides an introductory tutorial on conducting a simplified cost-utility analysis of a new treatment for a generic cariovascular disease, combining discrete event simulation (DES) and real-world data (RWD). To help readers understand the proposal, we present an application of this approach to a RWD database, along with files containing its implementation in Excel and R and the explanation in Spanish in the Supplementary material.
Method
This dataset was used to calculate quality-adjusted life years (QALY) and costs for each individual in the observed alternative (standard of care) by combining longitudinal and survival data. Simulated alternative (counterfactual) results were obtained by adding hazard ratios (HR) from published randomised clinical trials to the parametric survival analysis within a discrete event simulation (DES) model. Bootstrapping allowed to assess uncertainty. Life expectancy was estimated using parametric survival analysis in order to extend the analysis to the patient's death.
Results
The exercise files in Excel and R are available in the OSF repository (https://osf.io/gyuq9/overview?view_only=748bc600f59646f1b144e21458c50a42). These outline the steps for calculating the QALYs and costs for the standard and new alternatives based on the dataset. The incremental cost-effectiveness ratio is then calculated and the uncertainty of the result analysed using the cost-effectiveness plot and acceptability curve obtained via bootstrapping.
Conclusions
Combining real-world data and DES can enable cost-utility studies to be conducted, thus streamlining the process of economic evaluation. In order to apply this proposal to research studies, additional tools are required, such as probabilistic sensitivity analysis.
Introduction: Cost-effectiveness modeling often requires the extrapolation of survival data from clinical trials. The choice of extrapolation method is often uncertain and can have a profound effect on the results. We propose an approach that incorporates external evidence (eg, from published studies, registries, or el...
David McConnell, Arthur White, F. Lamrock et al.· Medical decision making· 0 citations
Background Parametric time-to-event (TTE) modeling is widely used in clinical trials to evaluate treatment response, patient prognosis, and drug-related adverse events (AEs). As follow-up assessments increasingly capture recurrent AEs, there is a growing need for analytical approaches that extend beyond traditional sin...
J. Seo, Hyeong-Seok Lim· Frontiers in Pharmacology· 1 citation
Two-sample survival probability curves (TSSPCs) provide a concise way to visualize treatment differences in randomized controlled trials (RCTs). In this paper, we propose various area under the curve (AUC) metrics for TSSPCs as numerical measures for treatment effects. First, in the same spirit as the restricted mean s...
Results of a clinical trial may misrepresent the target population. Inappropriate inclusion/exclusion criteria, selective recruitment, and differential participation may restrict the number of patients who consent to join the study. Frequently, they differ from the real-world population in terms of key outcome-related...
J. Efird, Genevieve N. Dupuis, Yuk-Ming Choi et al.· International Journal of Env...· 0 citations
This package implements methods for estimating and inferring the cumulative incidence functions for time-to-event (TTE) outcomes with intercur-rent events (ICE) under the five strategies outlined in the ICH E9 (R1) adden-dum.
Few of the alternate approaches to Hazard Ratio based Network Meta-Analysis are demonstrated by firstly reconstructing the time-to-event dataset from Kaplan Meier curves from results of clinical trials available in public domain using relevant software and then recomputing the restricted mean survival time (RMST) estim...
Amritendu Bhattacharya, Ravilisetty Revathi, B. Venkatesu· Sains Malaysiana· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.